TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
Key claim: A Phase 1 open-label trial is evaluating the PI3K-delta inhibitor TGR-1202 combined with ruxolitinib in patients with PV (resistant to hydroxyurea), PMF, PPV-MF, PET-MF, and MDS/MPN.
Abstract
This is a Phase 1, open-label, study of TGR-1202, a PI3K delta inhibitor, administered together with ruxolitinib in patients with myeloproliferative neoplasms (specifically: polycythemia vera, primary myelofibrosis, PPV-MF or PET-MF) and MDS/MPN.
Why this matters
This Phase 1 trial brings PI3K-δ inhibition into combination with ruxolitinib across an unusually broad MPN spectrum — hydroxyurea-resistant PV, primary and secondary MF, and MDS/MPN overlap — testing a shared mechanistic premise (dual JAK-STAT + PI3K-AKT blockade) in subtypes with very different natural histories. For PMF it joins roginolisib and IOA-244 as a third PI3Kδ+rux combination, while for PV and MDS/MPN it is among the first introductions of this axis, potentially exposing subtype-specific response differences to a common therapeutic backbone.